Wolverine Stack
BPC-157 + TB-500 · Tissue Repair & Recovery Protocol
Combines BPC-157 and TB-500 for synergistic tissue repair and recovery. 87.5% improvement in knee pain patients per Lee & Padgett 2021 study.
Overview
Combines BPC-157 and TB-500 for synergistic tissue repair and recovery. 87.5% improvement in knee pain patients per Lee & Padgett 2021 study.
BPC-157 increases actin production and modulates nitric oxide for vascular effects; TB-500 sequesters actin for cell migration; synergistic enhancement of fibroblast and immune cell movement to injury sites.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Both peptides show evidence for accelerated repair; BPC-157 improved Achilles tendon healing in animal models.
BPC-157 demonstrates enhanced muscle regeneration; TB-500 promotes cell migration essential for repair.
Lee & Padgett study showed 87.5% of knee pain patients improved with BPC-157/TB4 combination.
TB-500 Phase 2 trials showed approximately one month faster healing in ulcer patients.
Both peptides modulate inflammatory pathways through different mechanisms.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Peptide blend
- Typical dose
- BPC-157: 250-500 mcg per dose + TB-500: 2-2.5 mg per dose
- Frequency
- BPC-157: 1-2x daily; TB-500: 2x per week (typically Monday/Thursday or Tuesday/Friday)
- Cycle length
- 4-8 weeks for injury recovery; shorter for maintenance
- Storage
- Lyophilized powder: room temperature acceptable; Reconstituted: 2-8°C refrigerated for both peptides
Molecular data
- Type
- Peptide blend
Dosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| General Recovery Protocol | SubQ | BPC-157: 250mcg 2x/day + TB-500: 2mg 2x/week | BPC-157 daily, TB-500 twice weekly |
| Intensive Injury Recovery | SubQ near injury site | BPC-157: 500mcg 2x/day + TB-500: 2.5mg 2x/week | BPC-157 daily, TB-500 twice weekly |
| Maintenance/Prevention Protocol | SubQ | BPC-157: 250mcg 1x/day + TB-500: 2mg 1x/week | BPC-157 daily, TB-500 weekly |
| GI Support Protocol | Oral capsule or sublingual | BPC-157: 500mcg-1mg | Once daily on empty stomach |
Interactions
BPC-157 upregulates GH receptors; combined use may accelerate recovery.
GH secretagogues complement stack by increasing endogenous growth hormone.
MGF activates satellite cells; combined mechanisms may enhance muscle recovery.
Copper peptide promotes collagen; no negative interactions expected.
BPC-157 shows protective effects against NSAID-induced damage; long-term effects unknown.
Steroids may counteract healing; BPC-157 shown to reverse some steroid-induced damage in models.
Both peptides promote angiogenesis; monitor for bleeding issues.
Angiogenesis promotion could theoretically support tumor growth; contraindicated with cancer history.
Quality checklist
- ✓White or off-white lyophilized powder cake indicating proper freeze-drying
- ✓Crystal clear solution after reconstitution with bacteriostatic water
- ✓Certificate of Analysis with HPLC purity testing (>98%) and mass spectrometry verification
- !Minor clumping acceptable if dissolves completely with gentle swirling
- ×Collapsed, yellowed, or powder stuck to vial sides—may indicate degradation from heat
- ×Persistent cloudiness or visible particles after reconstitution—indicates contamination or degradation
What to expect
Safety
- Not extensively documented in human studies
- Generally well-tolerated in available research
- Any unusual lumps, growths, or rapid tissue changes
- Severe injection site reactions or infections
- Signs of allergic reaction (rash, swelling, difficulty breathing)
- Unexpected bleeding or bruising
- Persistent headaches or vision changes
- Any symptoms suggesting abnormal growth
- ANY history of cancer or suspicious growths
- Active malignancy or concurrent chemotherapy
- Pregnancy or breastfeeding
FAQ
What does the Lee & Padgett 2021 study mean by 87.5% knee pain improvement?
The study injected 16 patients with BPC-157 and TB-500 intra-articularly (directly into knees). Overall 87.5% (14/16) experienced relief - with BPC-157 alone showing 91.6% (11/12) and the combination showing 75% (3/4). These small sample sizes suggest effectiveness but need larger trials for clinical validation.
Should Wolverine Stack be injected at the injury site or systemically?
Both work, but local injection near injury sites concentrates effects and may accelerate healing faster. For joint injuries, intra-articular injection (like the Lee & Padgett study) may be superior to systemic SubQ injection. Systemic SubQ administration is more practical for non-accessible injuries and provides whole-body healing support.
How long does it take to see results from the Wolverine Stack?
Week 1-2: Possible inflammation reduction and initial recovery improvement. Week 2-4: Noticeable between-workout recovery improvements and reduced soreness. Week 4-8: Significant chronic injury improvement and structural tissue changes. Peak effects typically appear 6-8 weeks with proper consistency.
Can Wolverine Stack be used with growth hormone secretagogues like CJC-1295?
Yes, GH secretagogues (CJC-1295, Ipamorelin) complement Wolverine Stack synergistically. BPC-157 upregulates GH receptors while TB-500 enhances regeneration - adding endogenous GH amplifies tissue repair effects. This combination is particularly valuable for athletic recovery and serious injury rehabilitation.
References
- 1Thymosin Beta-4 Accelerates Wound HealingMalinda KM, Sidhu GS, Mani H, et al. · Journal of Investigative Dermatology · 1999
Rats, full thickness wounds: topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days, with increased collagen deposition and angiogenesis.
animalPubMed 10469335 ↗ - 2Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growthStaresinic, M., et al. · Journal of Orthopaedic Research · 2003
Superior tendon healing with improved biomechanical properties (increased load of failure and Young's modulus), enhanced tendon-to-bone integration, and stimulated tendocyte growth in rat models.
in-vitroPubMed 14554208 ↗ - 3The regenerative peptide thymosin beta-4 accelerates the rate of dermal healing in preclinical animal models and in patientsTreadwell, T., Kleinman, H.K., Crockford, D., Hardy, M.A., Guarnera, G.T., Goldstein, A.L. · Annals of the New York Academy of Sciences · 2012
In two Phase 2 clinical trials, thymosin beta-4 accelerated healing of chronic pressure ulcers and venous stasis ulcers by almost a month compared to placebo, with confirmed safety and tolerability.
animalPubMed 23050815 ↗ - 4Thymosin Beta-4: A Multi-Functional Regenerative Peptide. Basic Properties and Clinical ApplicationsGoldstein AL, Hannappel E, Sosne G, Kleinman HK · Expert Opinion on Biological Therapy · 2012
Comprehensive review: thymosin beta-4 promotes cell migration, mobilizes stem/progenitor cells, forms new blood vessels, regenerates tissue, and reduces inflammation, apoptosis, and scar formation.
reviewPubMed 22074294 ↗ - 5Intra-Articular Injection of BPC 157 for Multiple Types of Knee PainLee E, Padgett B · Alternative Therapies in Health and Medicine · 2021
16 patients, intra-articular injection: Overall 87.5% (14/16) experienced knee pain relief. BPC-157 alone: 91.6% improvement (11/12). BPC-157 + TB4 combination: 75% improvement (3/4).
reviewPubMed 34324435 ↗ - 6Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic ReviewVasireddi A, et al. · HSS Journal · 2025
36 articles reviewed (544 screened, 1993-2024). Preclinical models showed improvements in muscle tears, tendon ruptures, ligament tears, and fracture healing. Mechanism involves enhanced GH receptor expression and angiogenesis.
reviewPubMed 40756949 ↗